Can I read Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies on EtoBox?

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies by Ying, Zhitao (author);He, Ting (author);Wang, Xiaopei (author);Zheng, Wen (author);Lin, Ningjing (author);Tu, Meifeng (author);Xie, Yan (author);Ping, Lingyan (author);Zhang, Chen (author);Liu, Weiping (author);Deng, Lijuan (author);Wu, Meng (author);Feng, Feier (author);Leng, Xin (author);Du, Tingting (author);Qi, Feifei (author);Hu, Xuelian (author);Ding, Yanping (author);Lu, Xin-an (author);Song, Yuqin (author);Zhu, Jun (author) is a Medicine article available to read on EtoBox.

What is Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies about?

## Abstract ## Background The unprecedented efficacy of chimeric antigen receptor T (CAR-T) cell immunotherapy of CD19^+^ B-cell malignancies has opened a new and useful way for the treatment of malignant tumors. Nonetheless, there are still formidable challenges in the field of CAR-T cell therapy, such as the biodistribution of CAR-T cells in vivo. ## Methods NALM-6, a human B-cell acute lymphoblastic leukemia (B-ALL) cell line, was used as target cells. CAR-T cells were injected into a mice model with or without target cells. Then we measured the distribution of CAR-T cells in mice. In addition, an exploratory clinical trial was conducted in 13 r/r B-cell non-Hodgkin lymphoma (B-NHL) patients, who received CAR-T cell infusion. The dynamic changes in patient blood parameters over time after infusion were detected by qPCR and flow cytometry. ## Results CAR-T cells still proliferated over time after being infused into the mice without target cells within 2 weeks. However, CAR-T cells did not increase significantly in the presence of target cells within 2 weeks after infusion, but expanded at week 6. In the clinical trial, we found that CAR-T cells peaked at 7–21 days after infusion

Who reads Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies?

Author

Ying, Zhitao (author);He, Ting (author);Wang, Xiaopei (author);Zheng, Wen (author);Lin, Ningjing (author);Tu, Meifeng (author);Xie, Yan (author);Ping, Lingyan (author);Zhang, Chen (author);Liu, Weiping (author);Deng, Lijuan (author);Wu, Meng (author);Feng, Feier (author);Leng, Xin (author);Du, Tingting (author);Qi, Feifei (author);Hu, Xuelian (author);Ding, Yanping (author);Lu, Xin-an (author);Song, Yuqin (author);Zhu, Jun (author)

Publisher

Springer Science and Business Media LLC

Published

2021

Language

EN

Field

Medicine (Health Sciences)